Co-founded by faculty from Columbia University and University of Melbourne, Praxis Precision Medicines targets CNS disorders.
Praxis Precision Medicines, a US-based gene therapy developer focusing central nervous system disorders, collected $110m in series C1 funding yesterday from investors including pharmaceutical firm Novo Holdings.
Eventide Asset Management led the round, which also included Vida Ventures, Blackstone Life Sciences, OCV Partners, Avoro Capital Advisors, Surveyor Capital, Point72, Cormorant Asset Management, Qatar Investment Authority, Irving Investors, Adage Capital Management, Verition Fund Management and Ample Plus Fund.
Founded in 2015, Praxis Precision Medicines is developing gene therapies for…
